Search Results for: PIK3CA

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
CYTH2 cytohesin 2
  • Intra-Golgi traffic
  • Inositol 1,3,4,5-Tetrakisphosphate
  • Formic acid
  • 1D-myo-inositol 1,4,5-trisphosphate
  • S,S-(2-Hydroxyethyl)Thiocysteine
  • Brefeldin A
CYTH3 cytohesin 3
  • Intra-Golgi traffic
  • Inositol 1,3,4,5-Tetrakisphosphate
  • Inositol-(1,3,4,5,6)-Pentakisphosphate
DDX5 DEAD-box helicase 5
  • SUMOylation of transcription cofactors
  • mRNA Splicing - Major Pathway
  • Estrogen-dependent gene expression
  • Replication of the SARS-CoV-1 genome
  • Replication of the SARS-CoV-2 genome
  • Artenimol
  • Prostate cancer
DNAJB6 DnaJ heat shock protein family (Hsp40) member B6
  • Regulation of HSF1-mediated heat shock response
EGFR epidermal growth factor receptor
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • Signaling by EGFR
  • GRB2 events in EGFR signaling
  • GAB1 signalosome
  • SHC1 events in EGFR signaling
  • EGFR downregulation
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • EGFR interacts with phospholipase C-gamma
  • EGFR Transactivation by Gastrin
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signal transduction by L1
  • Constitutive Signaling by EGFRvIII
  • Inhibition of Signaling by Overexpressed EGFR
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • PTK6 promotes HIF1A stabilization
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Extra-nuclear estrogen signaling
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • HCMV Early Events
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Cetuximab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Alvocidib
  • IGN311
  • Matuzumab
  • Vandetanib
  • Rindopepimut
  • Canertinib
  • Pelitinib
  • Varlitinib
  • AV-412
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • PD-168393
  • Afatinib
  • Osimertinib
  • Necitumumab
  • Foreskin keratinocyte (neonatal)
  • Depatuxizumab mafodotin
  • Icotinib
  • Neratinib
  • Dacomitinib
  • Fostamatinib
  • Zalutumumab
  • Brigatinib
  • Olmutinib
  • Zanubrutinib
  • Abivertinib
  • Choriocarcinoma
  • Gastric cancer
  • Bladder cancer
  • Oral cancer
  • Glioma
  • Laryngeal cancer
  • Cervical cancer
  • Esophageal cancer
FANCC FA complementation group C
  • Fanconi Anemia Pathway
  • TP53 Regulates Transcription of DNA Repair Genes
  • Fanconi anemia
FASLG Fas ligand
  • Caspase activation via Death Receptors in the presence of ligand
  • Regulation by c-FLIP
  • RIPK1-mediated regulated necrosis
  • CASP8 activity is inhibited
  • Interleukin-4 and Interleukin-13 signaling
  • Dimerization of procaspase-8
  • FasL/ CD95L signaling
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • FOXO-mediated transcription of cell death genes
  • TNFs bind their physiological receptors
  • Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
FBP2 fructose-bisphosphatase 2
  • Gluconeogenesis
FTL ferritin light chain
  • Scavenging by Class A Receptors
  • Golgi Associated Vesicle Biogenesis
  • Neutrophil degranulation
  • Iron uptake and transport
  • Iron Dextran
  • Protoporphyrin
  • Ferric pyrophosphate
  • Sodium ferric gluconate complex
  • Ferric pyrophosphate citrate
  • Neurodegeneration with brain iron accumulation (NBIA); Hallervorden-Spatz syndrome; Neuroferritinopathy; Aceruloplasminemia
GABRB1 gamma-aminobutyric acid type A receptor subunit beta1
  • Signaling by ERBB4
  • GABA receptor activation
  • GABA receptor activation
  • Lorazepam
  • Ethchlorvynol
  • Enflurane
  • Temazepam
  • Butabarbital
  • Butalbital
  • Phenytoin
  • Etomidate
  • Talbutal
  • Pentobarbital
  • Clobazam
  • Meprobamate
  • Eszopiclone
  • Alprazolam
  • Lindane
  • Metharbital
  • Chlordiazepoxide
  • Amoxapine
  • Adinazolam
  • Lamotrigine
  • Medroxyprogesterone acetate
  • Clorazepic acid
  • Acamprosate
  • Midazolam
  • Flurazepam
  • Isoflurane
  • Primidone
  • Halazepam
  • Propofol
  • Diazepam
  • Oxazepam
  • Triazolam
  • Ethanol
  • Methoxyflurane
  • Memantine
  • Clonazepam
  • Methyprylon
  • Halothane
  • Desflurane
  • Flumazenil
  • Estazolam
  • Sevoflurane
  • Glutethimide
  • gamma-Hydroxybutyric acid
  • Camazepam
  • Delorazepam
  • Flunitrazepam
  • Ethyl loflazepate
  • Cloxazolam
  • Bromazepam
  • Clotiazepam
  • Fludiazepam
  • Ketazolam
  • Prazepam
  • Quazepam
  • Cinolazepam
  • Nitrazepam
  • Prasterone
  • Taurine
  • Brotizolam
  • Stiripentol
  • Etizolam
  • Thiocolchicoside
  • Brexanolone
  • Apalutamide
  • Remimazolam
  • Benzodiazepine
  • Pinazepam
  • Medazepam
  • Loprazolam
  • Doxefazepam
  • Lormetazepam
  • Nordazepam
  • Oxazepam acetate
  • Cinazepam
  • Bentazepam
  • Mexazolam
GALNT12 polypeptide N-acetylgalactosaminyltransferase 12
  • Defective GALNT12 causes colorectal cancer 1 (CRCS1)
  • O-linked glycosylation of mucins
GLIS2 GLIS family zinc finger 2
  • Nephronophthisis-medullary cystic kidney disease, including; Nephronophthisis (NPH) ; Nephronophthisis-like nephropathy 1; Medullary cystic kidney disease 1; Medullary cystic kidney disease 2 (MSKD2)
GNAQ G protein subunit alpha q
  • Acetylcholine regulates insulin secretion
  • Acetylcholine regulates insulin secretion
  • G alpha (q) signalling events
  • G alpha (q) signalling events
  • ADP signalling through P2Y purinoceptor 1
  • ADP signalling through P2Y purinoceptor 1
  • Thromboxane signalling through TP receptor
  • Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion
  • Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion
  • Thrombin signalling through proteinase activated receptors (PARs)
GRIN2B glutamate ionotropic receptor NMDA type subunit 2B
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • RAF/MAP kinase cascade
  • Neurexins and neuroligins
  • Synaptic adhesion-like molecules
  • MECP2 regulates neuronal receptors and channels
  • Activated NTRK2 signals through FYN
  • Assembly and cell surface presentation of NMDA receptors
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • Glutamic acid
  • Tramadol
  • Enflurane
  • Atomoxetine
  • Pentobarbital
  • Methadone
  • Secobarbital
  • Meperidine
  • Haloperidol
  • Acamprosate
  • Donepezil
  • Guaifenesin
  • Felbamate
  • Memantine
  • Phenobarbital
  • Aripiprazole
  • Tenocyclidine
  • Prasterone
  • Taurine
  • Milnacipran
  • EVT-101
  • Lumateperone
  • Acetylcysteine
  • Ketobemidone
  • Gavestinel
  • Ifenprodil
  • Magnesium acetate tetrahydrate
  • Magnesium carbonate
  • Esketamine
  • Esketamine
  • Fluciclovine (18F)
HRAS HRas proto-oncogene, GTPase
  • SOS-mediated signalling
  • Activation of RAS in B cells
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB4 signaling
  • Signaling by SCF-KIT
  • Signalling to RAS
  • p38MAPK events
  • p38MAPK events
  • GRB2 events in EGFR signaling
  • SHC1 events in EGFR signaling
  • Downstream signal transduction
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • Tie2 Signaling
  • EGFR Transactivation by Gastrin
  • DAP12 signaling
  • SHC-related events triggered by IGF1R
  • FCERI mediated MAPK activation
  • NCAM signaling for neurite out-growth
  • EPHB-mediated forward signaling
  • Ras activation upon Ca2+ influx through NMDA receptor
  • VEGFR2 mediated cell proliferation
  • CD209 (DC-SIGN) signaling
  • Constitutive Signaling by EGFRvIII
  • SHC-mediated cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Regulation of RAS by GAPs
  • RAF activation
  • RAF/MAP kinase cascade
  • MAP2K and MAPK activation
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • RAS signaling downstream of NF1 loss-of-function variants
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Insulin receptor signalling cascade
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • MET activates RAS signaling
  • Signaling by FGFR3 fusions in cancer
  • Signaling by FGFR3 point mutants in cancer
  • Activated NTRK2 signals through RAS
  • Erythropoietin activates RAS
  • Activated NTRK2 signals through FRS2 and FRS3
  • Activated NTRK3 signals through RAS
  • FLT3 Signaling
  • Constitutive Signaling by Overexpressed ERBB2
  • Estrogen-stimulated signaling through PRKCZ
  • RAS processing
  • RAS GTPase cycle mutants
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Hexane-1,6-Diol
  • Trifluoroethanol
  • Guanosine-5'-Triphosphate
  • Guanosine-5'-Diphosphate
  • N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE
  • Bladder cancer
  • Penile cancer
  • Squamous cell carcinoma
  • Thyroid cancer
  • Cervical cancer
  • Hepatocellular carcinoma
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
IL13RA2 interleukin 13 receptor subunit alpha 2
  • Interleukin-4 and Interleukin-13 signaling
  • AER001
IL24 interleukin 24
  • Interleukin-20 family signaling
IL3 interleukin 3
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • RAF/MAP kinase cascade
  • RUNX1 regulates transcription of genes involved in interleukin signaling
  • Interleukin receptor SHC signaling
  • Amlexanox
  • Zinc
  • Polaprezinc
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
IRS2 insulin receptor substrate 2
  • PI3K Cascade
  • IRS-mediated signalling
  • SOS-mediated signalling
  • SOS-mediated signalling
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • PI3K/AKT activation
  • PI3K/AKT activation
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • IRS-related events triggered by IGF1R
  • Signaling by Leptin
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • IRS activation
  • Signal attenuation
  • RET signaling
  • Signaling by Erythropoietin
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phospholipase C gamma (PLCG)
  • Erythropoietin activates STAT5
  • Erythropoietin activates RAS
  • Erythropoietin activates RAS
  • Growth hormone receptor signaling
IRS4 insulin receptor substrate 4
  • IRS-related events triggered by IGF1R

Page 2 out of 4 pages